Skip to main content
. Author manuscript; available in PMC: 2010 Feb 28.
Published in final edited form as: Arch Dermatol. 2008 Feb;144(2):173–180. doi: 10.1001/archderm.144.2.173

Table 1.

Patient Characteristics

Patient No./Sex/Age, y/Race CLE Type Old Medications New Medications
1/F/43/White Generalized DLE Hydroxychloroquine sulfate Lenalidomide
2/F/48/Black Generalized DLE Prednisone, hydroxychloroquine, quinacrine hydrochloride, azathioprine Azathioprine
4/F/42/White Localized DLE Hydroxychloroquine Thalidomide, methotrexate
6/F/48/White SCLE Chloroquine phosphate, quinacrine, hydroxychloroquine, prednisone Methotrexate
7/F/19/Asian Generalized DLE/SLE None Prednisone, hydroxychloroquine, Quinacrine, cyclophosphamide
8/F/83/Hispanic SCLE Hydroxychloroquine, prednisone Methotrexate
10/F/61/Black Generalized DLE Hydroxychloroquine, quinacrine, Hydroxychloroquine
11/F/50/Black Localized DLE/SLE Chloroquine, quinacrine, methylprednisolone, dapsone, methotrexate, cyclosporine, azathioprine Lenalidomide

Abbreviations: CLE, cutaneous lupus erythematosus; DLE, discoid lupus erythematosus; SCLE, subacute CLE; SLE, systemic lupus erythematosus.